MedTrace Logo

Weekly Single Fraction Hypofractionated Adjuvant Radiotherapy for Early Stage Breast Cancer

NCT04580784 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-10-08

No results posted yet for this study

Summary

The current study is a prospective phase II study; Eligible patients will receive hypofractionated Irradiation at a total dose of 28.5Gy in 5 once-weekly fractions of 5.7Gy in 5 weeks to the Whole Breast or chest wall with or without peripheral lymphatic irradiation.

Conditions

Interventions

RADIATION

Weekly hypofractionation for early breast cancer

Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks

Sponsors & Collaborators

  • Kasr El Aini Hospital

    collaborator OTHER

  • Mona Salem

    lead OTHER

Principal Investigators

  • Mona Salem, MSc · Kasr El AiniH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-10
Primary Completion
2020-11-30
Completion
2024-05-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04580784 on ClinicalTrials.gov